8-K: Kura Oncology Announces Positive Preliminary Data for Ziftomenib Combination Therapy and Secures $146 Million in Private Placement

Kura Oncology reports promising early clinical results for ziftomenib in combination with standard therapies for AML, alongside a successful $146 million private placement, extending their cash runway into 2027.

Summary

• Kura Oncology announced preliminary results from the KOMET-007 trial, evaluating ziftomenib in combination with standard of care treatments for acute myeloid leukemia (AML).
• The company's cash position as of December 31, 2023, was approximately $424 million.
• A recent private placement closed on January 26, 2024, generating approximately $146 million in net proceeds.
• The combined cash position is expected to fund operations into 2027.
• The KOMET-007 trial enrolled 20 patients between July and November 2023, including both newly diagnosed and relapsed/refractory AML patients.
• Ziftomenib at 200 mg daily was well-tolerated with no dose-limiting toxicities or drug-drug interactions observed.
• All five newly diagnosed patients treated with ziftomenib and cytarabine/daunorubicin (7+3) achieved a complete remission (CR).
• The overall response rate (ORR) among relapsed/refractory patients treated with ziftomenib and venetoclax/azacitidine was 53% (8/15).
• In menin inhibitor-naive patients, the CR/CRh rate was 56% (5/9).
• The company expects to complete enrollment of 85 patients in the KOMET-001 trial by mid-2024.

Sentiment

Score: 9

Explanation: The document presents very positive clinical data, a strong cash position, and a clear path forward, indicating a high level of confidence and optimism for the company's future.

Positives

• The company has a strong cash position of approximately $424 million, further bolstered by a $146 million private placement.
• The combined cash is expected to fund operations into 2027.
• Ziftomenib shows a promising safety profile with no dose-limiting toxicities, QTc prolongation, or drug-drug interactions observed.
• All newly diagnosed patients in the KOMET-007 trial achieved complete remission when treated with ziftomenib and 7+3.
• Ziftomenib in combination with venetoclax/azacitidine demonstrated a 53% overall response rate in relapsed/refractory AML patients.
• The CR/CRh rate in menin inhibitor-naive patients was 56%, indicating strong efficacy in this subgroup.
• The company is progressing with dose escalation and plans to initiate a Phase 1b dose validation/expansion study.
• The company is rapidly enrolling patients in its clinical trials.

Negatives

• The preliminary cash position is subject to finalization of financial closing procedures and audit, and actual results may differ.
• The information provided is preliminary and does not present all information necessary for a complete understanding of the company's financial condition.
• Some patients experienced Grade 3 treatment-emergent adverse events, although these were consistent with underlying disease and backbone therapies.
• The overall response rate in relapsed/refractory patients who had prior venetoclax treatment was 40%, which is lower than the overall response rate.

Risks

• The efficacy and safety of ziftomenib may not be consistent in later clinical trials.
• The company may not obtain regulatory approval for its product candidates.
• There are risks associated with performing clinical trials and regulatory filings.
• The company relies on third parties to conduct clinical trials.
• The company has cash needs and relies on outside financing to meet capital requirements.
• There are risks associated with discovering, developing, and commercializing drugs.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to complete enrollment in the KOMET-001 trial by mid-2024 and plans to initiate a Phase 1b dose validation/expansion study for ziftomenib in combination with venetoclax/azacitidine in newly diagnosed AML patients. The company's current cash position is expected to fund operations into 2027.

Management Comments

• Ziftomenib demonstrates potential to become a cornerstone of AML therapy.
• Combinations appear to mitigate the risk of differentiation syndrome.
• The company is encouraged by the preliminary evidence of clinical activity.
• The company is experiencing strong investigator enthusiasm as evidenced by rapid enrollment across studies.

Industry Context

The development of ziftomenib aligns with the broader industry trend of targeting foundational mutations in cancer to improve treatment outcomes. The combination approach with standard of care therapies is also a common strategy to enhance efficacy and manage resistance. The focus on AML, particularly in relapsed/refractory settings, addresses a significant unmet medical need.

Comparison to Industry Standards

• The 100% complete remission rate in newly diagnosed adverse-risk AML patients treated with ziftomenib and 7+3 is significantly higher than the anticipated 32-33% rate with 7+3 alone, as reported in Lancet et al. Blood. 2014 and Lin et al. Blood Adv. 2021.
• The 53% overall response rate in relapsed/refractory AML patients treated with ziftomenib and venetoclax/azacitidine is notable, especially considering the expected 35-45% CR/CRi rate in venetoclax-naive patients and the <10% ORR in KMT2A-r relapsed/refractory AML, as referenced from Stahl, M. et al., Blood Advances 5(5), 1552-1564 (2021) and Issa, Syndax ASH Investor Event (Dec. 2023).
• The response rates in venetoclax-experienced patients are also encouraging, given the expected 0-20% response rates following venetoclax failure, as noted in Zainaldin, C. et al., Lymphoma 63(13):3245-3248 (2022), Chan, O. and Walker, A., Hematology 702-708 (2023), and Maiti A, et al., Haematologica. 2021; 106(3):894-898.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and strong financial position favorably.
• Employees may be encouraged by the company's progress and extended cash runway.
• Patients with AML may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will determine a recommended Phase 2 dose in combination with venetoclax/azacitidine.
• The company will initiate a Phase 1b dose validation/expansion in combination with venetoclax/azacitidine in newly diagnosed patients with NPM1-m or KMT2A-r AML.
• The company will complete enrollment of 85 patients in the KOMET-001 trial by mid-2024.
• The company will dose first patients in KOMET-008 trial in combination with FLT3 inhibitor gilteritinib, LDAC and FLAG-IDA in Q1 2024.
• The company will initiate a post-transplant maintenance program in Q1 2024.
• The company will expand ziftomenib development to acute lymphoblastic leukemia (ALL) in Q1 2024.
• The company will provide the next KOMET-007 combination update in 2024.

Key Dates

Keywords

ziftomenib, acute myeloid leukemia, AML, menin inhibitor, KOMET-007, KOMET-001, clinical trial, complete remission, overall response rate, private placement, NPM1-mutant, KMT2A-rearranged, venetoclax, azacitidine, cytarabine, daunorubicin